Marstacimab (Hympavzi, Pfizer) is indicated for 'routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with:
severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors, or
severe haemophilia B (congenital factor IX deficiency, FIX <1%) without factor IX inhibitors'.
The dosage schedule is available in the summary of product characteristics for marstacimab.
The list price of marstacimab is confidential until published by the Department for Health and Social Care.
The company has a commercial arrangement (simple discount patient access scheme). This makes marstacimab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on the company's webpage on marstacimab (PDF only).